A Study of Two Macitentan Formulations in Healthy Adult Participants
Status:
Not yet recruiting
Trial end date:
2022-09-21
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the bioequivalence of macitentan on the primary
pharmacokinetics (PK) parameters between the dispersible final market image (FMI) macitentan
tablet and the opsumit tablet in healthy adult participants in fasted conditions.